短時間作用型インスリンの世界市場：洞察、競合情勢、市場予測：2030年

短時間作用型インスリンの市場規模は、2023年に70億1,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に3.55％のCAGRで拡大し、2030年には89億2,000万米ドルに達すると予測されています。座りがちなライフスタイルと不健康な食生活に煽られた糖尿病有病率の上昇により、血糖値を効果的に管理するためのインスリン療法の需要が増加しています。同時に、世界の糖尿病に対する認識と診断の高まりは、より多くの個人が治療を受けることを促し、市場拡大をさらに促進し、2024年から2030年までの予測期間中、短時間作用型インスリン製剤の市場を押し上げる要因となっています。

国際糖尿病連合（IDF）の最新データ（2021年）によると、糖尿病は20～79歳の成人人口の10.5%が罹患しており、罹患者の半数近くは自分の症状に気づいていない状態です。2045年に向けて、IDFの予測では糖尿病の有病率は大幅に上昇し、成人の8人に1人に当たる約7億8,300万人が糖尿病を患うと予想されており、これは46％の増加に相当します。したがって、世界の糖尿病有病率の増加は、予測期間中の短時間作用型インスリン市場を押し上げるとみられています。

さらに、世界保健機関（WHO）が提供した最近のデータと事実（2024年）によると、肥満は過剰な脂肪沈着によって引き起こされる慢性複合疾患であり、健康を損ない、糖尿病の発症リスクも高めるとされています。2022年には、18歳以上の成人で太りすぎの人が25億人おり、そのうち8億9,000万人が肥満と共存しています。肥満は脂肪細胞から炎症性化学物質を放出させ、インスリンに対する感受性を低下させる。脂肪細胞は、糖尿病の主な原因のひとつであるインスリンに反応する細胞の機能とインスリンに反応する能力を破壊します。このように、肥満が糖尿病の主要な危険因子の一つであるため、患者層が拡大し、短時間作用型インスリンに対する需要が高まっています。したがって、肥満の有病率の増加に伴い、糖尿病の有病率も増加し、市場における短時間作用型インスリンの需要が増加しています。

しかし、短時間作用型インスリン製品に対する規制当局の承認が厳しく、低血糖を発症するリスクがあるため、短時間作用型インスリン市場の成長には若干の障害が生じる可能性があります。

当レポートでは、世界の短時間作用型インスリン市場について調査し、市場の概要とともに、薬剤別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 短時間作用型インスリン市場レポートのイントロダクション

第2章 短時間作用型インスリン市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 短時間作用型インスリン市場の主な要因分析

• 短時間作用型インスリンの市場促進要因
• 短時間作用型インスリンの市場抑制要因と課題
• 短時間作用型インスリンの市場機会

第6章 短時間作用型インスリン市場におけるポーターのファイブフォース分析

第7章 短時間作用型インスリン市場の評価

• 薬剤別
  • リスプロ（ヒューマログ）
  • アスパルト（ノボログ/ノボラピッド）
  • グルリジン（アピドラ）
  • ヒューマリンR
  • ノボリンR
  • アクトラピッド
  • その他
• 流通チャネル別
  • 病院薬局
  • ドラッグストアと薬局
  • オンラインプロバイダー
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 短時間作用型インスリン市場の企業と製品プロファイル

• Eli Lilly and Company
• Novo Nordisk A/S
• Sanofi
• Biocon
• Torrent Pharmaceuticals Ltd.
• Gland Pharma
• Lupin
• Sensile
• Zydus Cadila
• Cipla
• Glenmark Pharmaceuticals
• Torrent Pharmaceuticals
• Pfizer
• GlaxoSmithKline
• Sun Pharmaceutical Industries
• Gan & Lee Pharmaceuticals
• ADOCIA SAS
• Geropharm LLC
• Wockhadt Ltd.
• Mannkind Corporation

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Short-Acting Insulin Market in Global (2021-2030)
• Table 3: Short-Acting Insulin Market in Global by Drug (2021-2030)
• Table 4: Short-Acting Insulin Market in Global by Distribution Channel (2021-2030)
• Table 5: Short-Acting Insulin Market in Global by Geography (2021-2030)
• Table 6: Short-Acting Insulin Market in North America (2021-2030)
• Table 7: Short-Acting Insulin Market in the United States (2021-2030)
• Table 8: Short-Acting Insulin Market in Canada (2021-2030)
• Table 9: Short-Acting Insulin Market in Mexico (2021-2030)
• Table 10: Short-Acting Insulin Market in Europe (2021-2030)
• Table 11: Short-Acting Insulin Market in France (2021-2030)
• Table 12: Short-Acting Insulin Market in Germany (2021-2030)
• Table 13: Short-Acting Insulin Market in United Kingdom (2021-2030)
• Table 14: Short-Acting Insulin Market in Italy (2021-2030)
• Table 15: Short-Acting Insulin Market in Spain (2021-2030)
• Table 16: Short-Acting Insulin Market in the Rest of Europe (2021-2030)
• Table 17: Short-Acting Insulin Market in Asia-Pacific (2021-2030)
• Table 18: Short-Acting Insulin Market in China (2021-2030)
• Table 19: Short-Acting Insulin Market in Japan (2021-2030)
• Table 20: Short-Acting Insulin Market in India (2021-2030)
• Table 21: Short-Acting Insulin Market in Australia (2021-2030)
• Table 22: Short-Acting Insulin Market in South Korea (2021-2030)
• Table 23: Short-Acting Insulin Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Short-Acting Insulin Market in the Rest of the World (2021-2030)
• Table 25: Short-Acting Insulin Market in the Middle East (2021-2030)
• Table 26: Short-Acting Insulin Market in Africa (2021-2030)
• Table 27: Short-Acting Insulin Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Short-Acting Insulin Market in Global (2021-2030)
• Figure 3: Short-Acting Insulin Market in Global by Drug (2021-2030)
• Figure 4: Short-Acting Insulin Market in Global by Distribution Channel (2021-2030)
• Figure 5: Short-Acting Insulin Market in Global by Geography (2021-2030)
• Figure 6: Short-Acting Insulin Market in North America (2021-2030)
• Figure 7: Short-Acting Insulin Market in the United States (2021-2030)
• Figure 8: Short-Acting Insulin Market in Canada (2021-2030)
• Figure 9: Short-Acting Insulin Market in Mexico (2021-2030)
• Figure 10: Short-Acting Insulin Market in Europe (2021-2030)
• Figure 11: Short-Acting Insulin Market in France (2021-2030)
• Figure 12: Short-Acting Insulin Market in Germany (2021-2030)
• Figure 13: Short-Acting Insulin Market in United Kingdom (2021-2030)
• Figure 14: Short-Acting Insulin Market in Italy (2021-2030)
• Figure 15: Short-Acting Insulin Market in Spain (2021-2030)
• Figure 16: Short-Acting Insulin Market in the Rest of Europe (2021-2030)
• Figure 17: Short-Acting Insulin Market in Asia-Pacific (2021-2030)
• Figure 18: Short-Acting Insulin Market in China (2021-2030)
• Figure 19: Short-Acting Insulin Market in Japan (2021-2030)
• Figure 20: Short-Acting Insulin Market in India (2021-2030)
• Figure 21: Short-Acting Insulin Market in Australia (2021-2030)
• Figure 22: Short-Acting Insulin Market in South Korea (2021-2030)
• Figure 23: Short-Acting Insulin Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Short-Acting Insulin Market in the Rest of the World (2021-2030)
• Figure 25: Short-Acting Insulin Market in the Middle East (2021-2030)
• Figure 26: Short-Acting Insulin Market in Africa (2021-2030)
• Figure 27: Short-Acting Insulin Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Market Opportunities
• Figure 31: PORTER'S Five Force Analysis

Short-acting Insulin Market by Drug (Lispro (Humalog), Aspart (NovoLog/NovoRapid), Glulisine (Apidra), Humulin R, Novolin R, Actrapid, and Others), Distribution Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Providers), and Geography (North America, Europe, Asia-Pacific, and rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of diabetes, increasing sedentary lifestyle and unhealthy diets, and growing awareness and diagnosis of diabetes across the globe.

The short-acting insulin market was valued at USD 7.01 billion in 2023, growing at a CAGR of 3.55% during the forecast period from 2024 to 2030 to reach USD 8.92 billion by 2030. The rising prevalence of diabetes, fueled by sedentary lifestyles and unhealthy diets, has led to an increasing demand for insulin therapy to manage blood glucose levels effectively. Simultaneously, rising awareness and diagnosis of diabetes globally have encouraged more individuals to seek treatment, further driving the market expansion, and thereby boosting the market for short-acting insulin products during the forecast period from 2024 to 2030.

Short-Acting Insulin Market Dynamics

According to the latest data provided by the International Diabetes Federation (2021), diabetes affects 10.5% of the adult population aged 20-79 years, with nearly half of those affected unaware of their condition. Looking ahead to 2045, IDF projections suggested that diabetes prevalence will rise significantly, with approximately 783 million adults, or 1 in 8, expected to be living with the condition, representing a 46% increase. Thus, the growing prevalence of diabetes worldwide will boost the market for short-acting insulin during the forecast period.

Additionally, as per the recent data provided by the IDF Atlas Report (2022), in 2022, there were 8.75 million people globally living with type 1 diabetes, with 1.52 million of them being under 20 years old. Additionally, as per the same source, there were 448,480 people in China, 79,226 in Japan, and 860,423 people in India living with type 1 diabetes in 2022. As a result, individuals with type 1 diabetes rely entirely on exogenous insulin to regulate their blood glucose levels. Short-acting insulin, also known as regular insulin, is crucial for managing postprandial blood sugar spikes, as it acts quickly to lower blood glucose levels after meals.

Furthermore, recent data and facts provided by the World Health Organization (2024), state that obesity is characterized as a chronic, complex disease caused by excessive fat deposits that can impair health and also increase the risk of developing diabetes. In 2022, there were 2.5 billion adults aged 18 years and older who were overweight, with 890 million among them living with obesity. Obesity causes fat cells to release pro-inflammatory chemicals, which can make the body less sensitive to insulin. Fat cells disrupt the function of insulin-responsive cells and their ability to respond to insulin, one of the major causes of diabetes. Thus, this large and expanding patient base increases the demand for short-acting insulin as obesity is one of the major risk factors for diabetes. Thus, with the increasing prevalence of obesity, the prevalence of diabetes also increases owing to the increase in demand for short-acting insulin in the market.

However, the stringent regulatory approvals for short-acting insulin products and the risk of developing hypoglycemia may result in slight obstacles to the growth of the short-acting insulin market.

Short-Acting Insulin Market Segment Analysis:

Short-acting Insulin Market by Drug (Lispro (Humalog), Aspart (NovoLog/NovoRapid), Glulisine (Apidra), Humulin R, Novolin R, Actrapid, and Others), Distribution Channel (Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Providers), and Geography (North America, Europe, Asia-Pacific, and rest of the World).

In the drug segment of the short-acting insulin market, the Humulin R category is estimated to amass a significant revenue share in the short-acting insulin market in 2023. Humulin R is a short-acting insulin that is identical to the insulin produced by the human pancreas. It has been widely used for many years and is well-established in clinical practice. Humulin R is generally less expensive compared to insulin analogs like Humalog (insulin lispro). Many healthcare providers and patients are familiar with Humulin R due to its long history of use. This familiarity can make it easier for patients to understand and manage their insulin therapy as Humulin, was the first human insulin produced using recombinant DNA technology, and was developed by Eli Lilly and Company in collaboration with Genentech. It was approved by the U.S. Food and Drug Administration (FDA) in 1982 and subsequently became available for medical use. This marked a significant advancement in diabetes treatment, as Humulin was the first insulin product identical to human insulin, offering a safer and more effective option compared to the animal-derived insulins that were previously used.

Humulin R can be administered via vial and syringe, which some patients prefer over insulin pens or pumps. Humulin R has a relatively stable duration of action, typically lasting around 4 to 6 hours. This stability can be beneficial for individuals who prefer a more predictable insulin effect.

Therefore, according to the above-mentioned factors Humulin R will register significant revenue growth, thereby driving the growth of the overall short-acting insulin market during the forecast period.

North America Is Expected To Dominate The Overall Short-Acting Insulin Market:

North America is expected to account for the highest proportion of the short-acting insulin market in 2023, out of all regions. The market for short-acting insulin in North America is experiencing significant growth driven by several key factors. Firstly, there has been a notable increase in the diabetic population across the region. This rise is attributed to factors such as an aging population, increasing obesity rates, and a growing sedentary lifestyle, which collectively contribute to higher incidences of diabetes. Additionally, there has been a growing emphasis on diabetes awareness and education programs throughout North America. These initiatives aim to educate the public about the risks associated with diabetes, the importance of early diagnosis, and the benefits of proper diabetes management thereby boosting the market of short-acting insulin in North America.

As per the IDF Atlas Report (2022), in 2022 approximately 1,447,298 people in the United States had type 1 diabetes, 285,324 people in Canada, and 89,834 people in Mexico had type 1 diabetes in 2022. Thus, type 1 diabetes is an autoimmune disease where the body's immune system destroys insulin-producing beta cells in the pancreas, necessitating lifelong insulin therapy for blood glucose management. Short-acting insulin is essential for individuals with type 1 diabetes to control postprandial blood sugar spikes and maintain overall glycemic control thereby boosting the market of short-acting insulin.

For instance, as per the International Diabetes Federation (IDF), Diabetes Atlas Tenth Edition 2021, in 2021, approximately 51 million adults (20-79 years) were living with diabetes in North America and the total number of people living with diabetes is projected to rise to 7 million by 2030 and 63 million by 2045. As per the same source, it is estimated that almost 1 in 4 (240 million) adults living in North America with diabetes are undiagnosed. Moreover, as per the IDF, Diabetes Atlas Tenth edition 2021, in 2021, more than 1.2 million children and adolescents (0-19 years) were living with type 1 diabetes, and one in six live births (21 million) were affected by diabetes during pregnancy.

Furthermore, an unhealthy lifestyle is a major factor contributing to an increase in the prevalence of chronic diseases like diabetes. As per the Centers for Disease Control and Prevention (CDC), 2021, fewer than 1 in 10 adults and adolescents eat enough fruits and vegetables, and 9 in 10 Americans aged 20 years or older consume more than the recommended amount of sodium. Moreover, only one in four is exclusively breastfed through six months of age, leading to a weak immune system. Thus, the prevalent unhealthy lifestyle in the region is one of the major factors contributing to the growing prevalence of diabetes, which in turn will increase the market for short-acting insulin, during the forecast years.

Government programs that raise awareness about diabetes and its symptoms can lead to earlier diagnosis. When more people are diagnosed with diabetes, especially type 1 diabetes which requires insulin therapy, the demand for short-acting insulin increases. For instance, in November 2023, PAHO, in collaboration with WHO, hosted a hybrid event in Mexico City to commemorate World Diabetes Day 2023, which was broadcast via Zoom. The event highlighted regional successes, challenges, and opportunities in diabetes prevention and control. Thus, these awareness programs can significantly boost the market for short-acting insulin by increasing awareness, advocating for supportive policies, improving access, facilitating information exchange, engaging stakeholders, addressing regional needs, launching awareness campaigns, and building capacity among healthcare professionals.

Thereby the factors mentioned are collectively responsible for escalating the overall market of short-acting insulin in the region during the forecast period.

Short-Acting Insulin Market Key Players:

Some of the key market players operating in the short-acting insulin market include Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Torrent Pharmaceuticals Ltd., Gland Pharma, Lupin, Sensile, Zydus Cadila, Cipla, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Pfizer, GlaxoSmithKline, Sun Pharmaceutical Industries, Gan & Lee Pharmaceuticals, ADOCIA SAS, Geropharm LLC, Wockhadt Ltd., Mannkind Corporation, and others.

Recent Developmental Activities In The Short-Acting Insulin Market:

• In March 2024, Novo Nordisk announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization for Awiqli(R) (once-weekly basal insulin icodec) for the treatment of diabetes in adults.
• In March 2023, Sanofi reduced the U.S. list price of Lantus(R), its most-prescribed insulin, by 78% and capped the out-of-pocket cost of Lantus(R) at $35 for all patients with commercial insurance.
• In July 2021, The U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, intended to enhance glycemic control in adults and pediatric patients with Type 1 diabetes mellitus, as well as in adults with Type 2 diabetes mellitus.
• In June 2021, Sanofi announced that a new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) has met its primary and secondary endpoints in adults with type 2 diabetes uncontrolled on insulin and one or two oral anti-diabetic medicines.

Key Takeaways From The Short-Acting Insulin Market Report Study

• Market size analysis for current short-acting insulin size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the short-acting insulin market.
• Various opportunities available for the other competitors in the short-acting insulin market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current short-acting insulin market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for short-acting insulin market growth in the coming future?

Target Audience Who Can Be Benefited From This Short-Acting Insulin Market Report Study

• Short-acting insulin product providers
• Research organizations and consulting companies
• Short-acting insulin-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in short-acting insulin
• Various end-users who want to know more about the short-acting insulin market and the latest technological developments in the short-acting insulin market.

Frequently Asked Questions For The Short-Acting Insulin Market:

1. What is short-acting Insulin?

Short-acting insulin is a type of insulin that acts quickly to lower blood glucose levels after meals. They are typically used to control blood sugar spikes that occur after eating.

2. What is the market for short-acting insulin?

The short-acting insulin market was valued at USD 7.01 billion in 2023, growing at a CAGR of 3.55% during the forecast period from 2024 to 2030 to reach USD 8.92 billion by 2030.

3. What are the drivers for the short-acting insulin market?

The demand for short-acting insulin is primarily being boosted by the rising prevalence of diabetes, fueled by sedentary lifestyles and unhealthy diets, had led to an increasing demand for insulin therapy to manage blood glucose levels effectively. Simultaneously, rising awareness and diagnosis of diabetes globally have encouraged more individuals to seek treatment, further driving the market expansion, and thereby boosting the market for short-acting insulin products during the forecast period from 2024 to 2030.

4. Who are the key players operating in the short-acting insulin market?

Some of the key market players operating in the short-acting insulin are Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Torrent Pharmaceuticals Ltd., Gland Pharma, Lupin, Sensile, Zydus Cadila, Cipla, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Pfizer, GlaxoSmithKline, Sun Pharmaceutical Industries, Gan & Lee Pharmaceuticals, ADOCIA SAS, Geropharm LLC, Wockhadt Ltd., Mannkind Corporation, and others.

5. Which region has the highest share in the short-acting insulin market?

North America is expected to account for the highest proportion of the short-acting insulin market in 2023, out of all regions. Firstly, there has been a notable increase in the diabetic population across the region. This rise is attributed to factors such as an aging population, increasing obesity rates, and changes in dietary habits, which collectively contribute to higher incidences of diabetes. Additionally, there has been a growing emphasis on diabetes awareness and education programs throughout North America. These initiatives aim to educate the public about the risks associated with diabetes, the importance of early diagnosis, and the benefits of proper diabetes management thereby boosting the market of short-acting insulin.

Table of Contents

1. Short-Acting Insulin Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Short-Acting Insulin Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Short-Acting Insulin Market Key Factors Analysis

• 5.1. Short-Acting Insulin Market Drivers
  • 5.1.1. Growing prevalence of diabetes
  • 5.1.2. Increase in sedentary lifestyles and unhealthy diets
  • 5.1.3. Increased awareness and diagnosis of diabetes across the globe
• 5.2. Short-Acting Insulin Market Restraints and Challenges
  • 5.2.1. Stringent regulatory concerns
  • 5.2.2. Risk of developing hypoglycemia
  • 5.2.3. Prolonged use of short-acting insulin can sometimes lead to insulin resistance.
• 5.3. Short-Acting Insulin Market Opportunities
  • 5.3.1. Increasing research and development for the integration of recombinant and synthetic human short-acting insulin

6. Short-Acting Insulin Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Short-Acting Insulin Market Assessment

• 7.1. By Drug
  • 7.1.1. Lispro (Humalog)
  • 7.1.2. Aspart (NovoLog/NovoRapid)
  • 7.1.3. Glulisine (Apidra)
  • 7.1.4. Humulin R
  • 7.1.5. Novolin R
  • 7.1.6. Actrapid
  • 7.1.7. Others
• 7.2. By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Drug Store & Retail Pharmacies
  • 7.2.3. Online Providers
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.1.2. Canada Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.1.3. Mexico Short-Acting Insulin Market Size in USD Million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.2.2. Germany Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.2.3. United Kingdom Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.2.4. Italy Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.2.5. Spain Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.2.6. Rest of Europe Short-Acting Insulin Market Size in USD Million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.3.2. Japan Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.3.3. India Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.3.4. Australia Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.3.5. South Korea Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Short-Acting Insulin Market Size in USD Million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.4.2. Africa Short-Acting Insulin Market Size in USD Million (2021-2030)
    • 7.3.4.3. South America Short-Acting Insulin Market Size in USD Million (2021-2030)

8. Short-Acting Insulin Market Company and Product Profiles

• 8.1. Eli Lilly and Company
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Novo Nordisk A/S
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Sanofi
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Biocon
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Torrent Pharmaceuticals Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Gland Pharma
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Lupin
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Sensile
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Zydus Cadila
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Cipla
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Glenmark Pharmaceuticals
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Torrent Pharmaceuticals
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Pfizer
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. GlaxoSmithKline
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Sun Pharmaceutical Industries
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Gan & Lee Pharmaceuticals
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. ADOCIA SAS
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Geropharm LLC
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Wockhadt Ltd.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Mannkind Corporation
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us